homehealthcare News

Pfizer, BioNTech start combined trials of COVID 19 vaccine candidate in Japan

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan
Profile image

By Reuters Oct 20, 2020 12:06:24 PM IST (Updated)

Pfizer, which is developing the vaccine with German partner BioNTech, has said it may confirm if the vaccine is effective as soon as this month.

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus. The study will recruit 160 people aged from 20 to 85, the firms said in a statement. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.

Recommended Articles

View All

Pfizer, which is developing the vaccine with German partner BioNTech, has said it may confirm if the vaccine is effective as soon as this month but also needs safety data from a global trial of 44,000 people that will not be available until next month.
Japan has pledged to secure enough vaccine supply for its entire population by the middle of 2021. In addition to Pfizer, it has struck deals on supplies with AstraZeneca Plc and other overseas makers of vaccine candidates.
Clinical trials of AstraZeneca and Oxford University’s experimental COVID-19 vaccine resumed in Japan this month after being put on hold over the illness of a British volunteer.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng